Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Valutazione di EXL01, un nuovo prodotto bioterapeutico vivo per prevenire la recidiva dell'infezione da Clostridioides Difficile nei pazienti ad alto rischio (LIVEDIFF)

19 ottobre 2026 aggiornato da: Hospices Civils de Lyon

Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors.

Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI.

In this context, fecal microbiota transplantation (FMT) has been validated for over 10 years for the prevention of recurrence in multi-recurrent CDI. The principle of FMT is based on the use of a pharmaceutical preparation made from the stool of a healthy donor, administered within the digestive tract of a patient for therapeutic purposes.

Currently, in the case of multiple recurrences, it is the recommended first-line treatment (from 2 recurrences) and the most effective, with a clinical efficacy preventing recurrence of CDI in 69% to 89% of cases at 8 weeks post-treatment, with a good safety profile.

Among the microbial factors promoting CDI, the loss of the bacterial species Faecalibacterium prausnitzii constitutes a specific therapeutic target. F. prausnitzii is a commensal bacterium of the human gut, making up nearly 5% of the fecal microbiota, and has been shown to be associated with an individual's state of health. A drop in its relative abundance is associated with an increased risk of numerous diseases, such as Crohn's disease and colorectal cancer. In CDI, F prausnitzii is greatly diminished. Moreover, low abundance of F. prausnitzii is predictive of C. difficile recurrence. Its abundance in stools is increased after FMT and is also predictive of response to treatment. From a pathophysiological point of view, one of the preventive effects of F. prausnitzii on recurrence would be mediated by its ability to hydrolyze the bile acids involved in the germination of C. difficile spores.

The aim of this Phase I/II trial is to assess the efficacy and safety of oral administration of EXL01, a single isolated unmodified strain of F. prausnitzii, in preventing CDI recurrence in high-risk patients at W8. The study will be conducted in 2 parts. The phase I (Part A) is planned to include 6 patients. The phase II (Part B) will include 50 patients in two arms (25 patients respectively in the placebo and EXL01 arm).

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

56

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Annecy, Francia
        • Non ancora reclutamento
        • CH Annecy Genevois Service de Maladies infectieuses
        • Contatto:
        • Investigatore principale:
          • Emilie PIET, MD
      • Clermont-Ferrand, Francia, 63003
        • Reclutamento
        • Service d'hépato-gastroentérologie - CHU Estaing
        • Contatto:
        • Investigatore principale:
          • Julien SCANZI, MD
      • Grenoble, Francia
        • Reclutamento
        • CHU Grenoble Service Maladies infectieuses et tropicales
        • Contatto:
        • Investigatore principale:
          • Salomé GALLET, MD
      • Lille, Francia
        • Reclutamento
        • CHU Lille Unité des Maladies Infectieuses et tropicales
        • Contatto:
        • Investigatore principale:
          • Sarah STABLER, MD
      • Lyon, Francia, 69004
        • Reclutamento
        • Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse
        • Contatto:
        • Investigatore principale:
          • Nicolas BENECH, MD
        • Contatto:
      • Marseille, Francia
        • Reclutamento
        • APHM La Timone Service de Maladies infectieuses
        • Contatto:
        • Investigatore principale:
          • Nadim CASSIR, MD
      • Paris, Francia, 75012
        • Reclutamento
        • Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP)
        • Contatto:
        • Investigatore principale:
          • Paul MCLELLAN, MD
      • Saint-Etienne, Francia, 42100
        • Reclutamento
        • Service d'infectiologie - Hôpital Nord / CHU Saint Etienne
        • Contatto:
        • Investigatore principale:
          • Elisabeth BOTHELO-NEVERS, Pr
      • Toulouse, Francia, 31059
        • Reclutamento
        • Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse
        • Investigatore principale:
          • Laurent ALRIC, Pr
        • Contatto:
      • Valence, Francia, 26000
        • Reclutamento
        • Service de Maladies Infectieuses - CH de Valence
        • Contatto:
        • Investigatore principale:
          • Amélie DUREAULT, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adult patient ≥18 years of age

  • ≥3rd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in stool by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI or 2nd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in the stools by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI with at least one of the following risk factors:

    • Age ≥70 years
    • Chronic renal failure (haemodialysis or GFR<60ml/min
    • History of severe or severe-complicated CDI (excluding current episode) according to ESCMID 2021 criteria
    • ≥3 CDI in the last 12 months (including current episode)
    • CDI associated with care defined as CDI occurring during hospitalisation (<3 months)
  • On current or planned vancomycin treatment per os

  • Patient able to give free, informed and written consent

  • Enrolled in compulsory national social security scheme

Exclusion Criteria:

  • Currently participating or has participated in a study with an investigational compound or device within 3 months prior to the first dose of the study intervention.
  • Severe C. difficile infection severe (defined by the presence of a white blood cell count >15×10⁹ cells/L or a body temperature >38.5°C or >50% increase in the patient's baseline creatinine related to CDI at the time of V1) and/or complicated (defined by any of the factors attributed to current Clostridioides difficile infection (CDI): hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, intestinal perforation or any fulminant course of the disease)
  • Refractory C. difficile infection defined as lack of response to well-conducted per os vancomycin or fidaxomicin treatment with ≥3 liquid stools per day after ≥5 days of treatment
  • Cirrhosis with Child C score
  • Hospitalization in continuing care unit or intensive care unit
  • Personal history of gastrointestinal resection other than appendectomy (gastrectomy, esophagectomy, colonic or small bowel resection, short small bowel syndrome).
  • Personal history of gastrointestinal resection resulting in chronic diarrhea (>3 loose stools per day)
  • Inflammatory bowel disease
  • Proven uncontrolled celiac disease
  • Current stoma (ileostomy or colostomy) or within the last 6 months, or any other intra-abdominal surgery within the 3 months prior to treatment
  • major surgery or trauma ≤ 4 weeks before the start of treatment or, if > 4 weeks ago, with an unresolved healing process that could affect the assessment or safety of the study treatment.
  • Antibiotic therapy in progress or planned during the study for an infection other than CDI
  • Surgery scheduled during the study requiring perioperative antibiotics.
  • -Women without contraception*, pregnant or breastfeeding women
  • History of hypersensitivity to EXL01 and/or to any of its excipients (D-mannitol, sucrose, maltodextrin, L-cysteine, L-cysteine hydrochloride, magnesium stearate and hydroxypropylmethylcellulose), and/or to soy or soy-containing products.
  • History of hypersensitivity to vancomycin as mentioned in local prescribing information.
  • Personal history of fecal microbiota transplantation < 6 months
  • Persons deprived of liberty by judicial or administrative decision
  • Adults under legal protection or unable to give consent
  • Swallowing disorders making oral treatment impossible
  • Participation in another interventional study within 3 months prior to inclusion. (Patients who have entered the follow-up phase of an interventional study may participate provided that more than 3 months have elapsed since the last intervention).
  • Expected life expectancy of less than 6 months
  • Presents a known psychiatric disorder that would interfere with adequate cooperation with study requirements.
  • Regular use of illicit or recreational drugs that may interfere with the administration of the medication or the interpretation of the data
  • History of chronic diarrhea (> 3 watery stools per day for > 4 weeks) not related to gastrointestinal infection.
  • Clinically significant medical or surgical condition not mentioned in the above criteria which, in the opinion of the investigator, could interfere with the administration of study drug, the interpretation of study safety or efficacy data, or compromise the safety or well-being of the subject.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Parte A (etichetta aperta EXL01)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
Sperimentale: Parte B (EXL01)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
Comparatore placebo: Parte B (placebo)

Following a at least 10-days vancomycin treatment:

Oral placebo including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Treatment-Emergent Adverse Events
Lasso di tempo: at Week 1, Week 2, Week 4, Week 8, Week 16

Phase I The primary endpoint is the occurrence of serious adverse events (CTCAE grade≥3) during treatment and follow-up and discontinuation of treatment due to adverse events attributed to treatment

at Week 1, Week 2, Week 4, Week 8, Week 16
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Lasso di tempo: at Week 8

Phase II The primary endpoint is the proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of CDI-specific treatment.

at Week 8

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Lasso di tempo: at Week 8

Phase I Proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of specific treatment for CDI.

at Week 8
Evaluation of the safety and tolerability profile of oral EXL01
Lasso di tempo: at Week 2, Week 4, Week 8, Week 16

Phase II Occurrence of adverse events (CTCAE grade≥3) during treatment and follow-up, and discontinuation of treatment due to adverse events

at Week 2, Week 4, Week 8, Week 16
Number of stools per day over the past 24 hours
Lasso di tempo: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Lasso di tempo: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Lasso di tempo: at Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Number of stools per day over the past 24 hours
Lasso di tempo: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Lasso di tempo: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Lasso di tempo: at Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Assessment of patient quality of life during treatment and follow-up
Lasso di tempo: At Week 8 and Week 16

Phases I and II Patient quality of life at W8 and M4 measured by a validated digestive disease quality of life questionnaire (GIQLI)

At Week 8 and Week 16
Assessment of recurrence of C. difficile infection
Lasso di tempo: At Week 16

Phases I and II percentage of patients with recurrence of C. difficile infection at M4

At Week 16
Evaluation of the presence of EXL01 in the fecal microbiota
Lasso di tempo: At Week 8

Phases I and II Level of F. prausnitzii (qPCR) in stool at W8 versus W0

At Week 8
Assessment of EXL01 persistence in the intestinal microbiota
Lasso di tempo: At Week 0 and Week 16

Phases I and II Level of F. prausnitzii (qPCR) in stool at M4 versus W0

At Week 0 and Week 16
16S rRNA sequencing or shotgun
Lasso di tempo: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Gut microbiota composition at each visit

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
16S rRNA sequencing or shotgun
Lasso di tempo: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Gut microbiota composition at each visit

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Lasso di tempo: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Lasso di tempo: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of recurrences of C. difficile infection requiring hospitalization
Lasso di tempo: At Week 8

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at W8

At Week 8
Assessment of recurrences of C. difficile infection requiring hospitalization
Lasso di tempo: at Week 16

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at M4

at Week 16
Assessment of recurrences of C. difficile infection requiring surgery
Lasso di tempo: at Week 8

phases I and II phases I and II percentage of patients with a recurrence of C. difficile infection requiring surgery at W8

at Week 8
Assessment of recurrences of C. difficile infection requiring surgery
Lasso di tempo: at Week 16

phases I and II percentage of patients with recurrent C. difficile infection requiring surgery at M4

at Week 16

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Nicolas BENECH, MD, Hospices Civils de Lyon

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 maggio 2024

Completamento primario (Stimato)

7 gennaio 2028

Completamento dello studio (Stimato)

7 gennaio 2028

Date di iscrizione allo studio

Primo inviato

21 febbraio 2024

Primo inviato che soddisfa i criteri di controllo qualità

5 marzo 2024

Primo Inserito (Effettivo)

12 marzo 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 69HCL22_0980
  • 2023-506232-32-00 (Altro identificatore: EU CT Number)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi